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Abstract Cardiovascular atherosclerotic diseases repre-
sent the main cause of death in the developed and
developing populations. Although major progress has
been made in the management of the classical modifiable
cardiovascular risk factors, unhealthy lifestyle conduces
to an increasing prevalence of overweight, obesity,
metabolic disorders, type 2 diabetes mellitus, premature
atherosclerosis and cardiovascular diseases. That is why
cardio-metabolic risk prediction should be superior in the
primary prevention of atherosclerosis and cardiovascular
diseases. Up-to-date primary preventive strategies according
to the European Guidelines, especially the high risk strategy
approach, are being implemented. Individual cardiovascular
and better cardio-metabolic risk assessment represents the
basic approach in the individualized primary prevention of
cardiovascular diseases and type 2 diabetes mellitus. Cardio-
metabolic biomarkers, especially high sensitivity C-reactive
protein, albuminuria, N-terminal pro-brain natriuretic peptide,
and imaging procedures (carotid intima-media thickness
measured by ultrasound) could improve the prediction of
cardiovascular diseases and type 2 diabetes beyond that using
traditional risk factors.
Keywords Cardiovascular risk prediction . Primary
prevention . Personalized cardio-metabolic risk . Imaging
procedures . Cardio-metabolic biomarkers
Introduction
A recent report from the World Health Organization
(WHO) identified six risk factors as the leading global risk
factors for death all over the world: high blood pressure,
tobacco smoking, physical inactivity, overweight or obesity,
and high cholesterol (C) levels. These factors contribute to
a large proportion of the deaths from cardiovascular
diseases (CVD), metabolic disorders, and cancer. These
chronic noncommunicable diseases, the majority of which
are preventable, are linked to the global lifestyle changes.
The impact of long-term treatment and adverse effects on
the quality of life, productivity, and disability take
devastating tolls on the economic situation of individuals
and societies alike [1].
Despite the decreasing rates of cardiovascular mortal-
ity in West European countries at the end of the 20th
century, but in Poland and Czech Republic from the East
European countries only, CVD have been the most
common cause of mortality during the last 50 years.
More than half of the European populations die from
CVD, mostly from ischemic heart disease (Fig. 1) [2].
That is why many activities of the European Society of
Cardiology and, consequently, national societies of Cardi-
ology are focused on preventive approaches to the most
common cause of death, i.e., CVD. It was particularly the
European Association for Cardiovascular Prevention and
Rehabilitation (EACPR) [formerly the Working Group on
Epidemiology and Prevention of Cardiovascular Diseases
of the European Society of Cardiology], has consistently
addressed this issue and developed the Joint Task Force
Recommendations on CVD Prevention in cooperation
with other medical societies regularly at a 4-year interval
since 1994 [3].
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However, although impressive progress has been made
in the management of the classical modifiable CVD risk
factors (hypertension, hypercholesterolemia) in high risk
individuals in CVD primary prevention, sedentary life-
style and intake of high energy diet as well as tobacco
smoking in a proportion of the population, represent
typical up-to date lifestyle habits in the majority of
European countries. These lifestyle habits conduce to the
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Fig. 1 Mortality of ischemic heart disease in European and other
countries [2]. CARK - 5 central Asian republics including Kazakhstan,
CIS - 12 countries of the “Commonwealth of Independent States”, EU –
European Union, Eur-A – Western European countries, Eur – B+C –
Middle and Eastern European countries
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increasing prevalence of overweight, obesity, metabolic
disorders, and type 2 diabetes mellitus (T2DM) (Fig. 2)
[2]. Many studies over the past years have shown that
especially intra-abdominal fat accumulation is the link to a
cluster of emerging metabolic risk factors that may
increase the risk of T2DM and CVD. Metabolic abnor-
malities such as abdominal fatty tissue distribution,
atherogenic dyslipidemia defined as elevated triglycerides
(TG) concentration and reduced high-density lipoprotein
(HDL)-C, impaired glucose homeostasis and elevated
blood pressure cluster in subjects with insulin resistance
(see below). These clustered risk factors were termed as
“metabolic syndrome” (MS).
The relative risk (RR) for cardiovascular events in
subjects with MS and even more so in diabetic subjects is
significantly increased; 2 to 3 times in men and 3 to 4
times in women, respectively compared with subjects
without MS and without T2DM, respectively [4, 5]. The
increased risk of CVD in T2DM subjects was only partly
explained by hyperglycemia and only partly by other
concomitant risk factors. The majority of patients with
T2DM die from CVD [6]. Should the increasing trend of
T2DM prevalence continue, the incidence of CVD will
rise again! That is why preventive cardiologists have to
pay utmost attention to the primary prevention of
metabolic problems, and prevention of the growing
incidence of T2DM in particular.
Cardiovascular diseases are multifactorial diseases
In the early years of the preventive cardiology era, which
come into being after the 2nd World War, atherosclerotic
CVD were represented by ischemic heart disease only, to be
joined by ischemic stroke, atherosclerotic stenosis of
carotid arteries, peripheral occlusive arterial diseases, etc.
later. Although atherosclerotic vascular diseases seem to be
a more appropriate term for the above conditions, the term
CVD has not been discarded in the majority of research
papers. Epidemiologists and preventive cardiologists
assessed and tested many causal risk factors for CVD,
using cardiovascular epidemiological methods: increased
plasma total C and/or low density lipoprotein (LDL)-C
levels, tobacco smoking, increased blood pressure, age, and
male sex. Causal risk factors have to met significant
statistical criteria such as long-term, strong, specific, and
time dependent association between the risk factor and
disease. These criteria were tested in large epidemiological
prospective and interventional trials [7, 8].
Cardiovascular diseases are multifactorial ones; various
risk factors for CVD on the one hand, and genetic
background on the other are both crucial preconditions for
clinical manifestation of CVD. The genotype for the CVD
phenotype is much more complicated; there are several
variants of genes involved in lipid metabolism, hyperten-
sion, coagulation, endothelial function, etc. Individualized
Fig. 2 Prevalence of type 2 diabetes mellitus in European and other countries [2], CARK - 5 central Asian republics including Kazakhstan, CIS -
12 countries of the “Commonwealth of Independent States”, Eur – B+C – Middle and Eastern European countries
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CVD prediction based on genetic testing is not available for
clinical application yet because of several interactions
between genes with each other and between genes and
environmental factors. In everyday practice, a positive
family history of CVD is useful for more precise CV risk
assessment only; premature manifestation of any CVD in
first-degree relatives (parents, son, daughter, brother, sister)
in males under 55 years of age and in females under
65 years of age increases the risk of CVD about 50–70% as
compared with subjects without a positive family history
[3].
Since the late 1970s, new risk factors for CVD, so called
emerging risk factors, including especially metabolic
factors, have been identified. The first of these new
metabolic risk factors was insulin resistance, i.e., a low
sensitivity of cells and tissues to insulin-mediated glucose
uptake. Together with compensatory hyperinsulinemia,
abdominal distribution of adipose tissue, impaired glucose
homeostasis (such as impaired fasting glucose, impaired
glucose tolerance tested after a standard oral glucose load
or T2DM), increased plasma TG levels and decreased
protective HDL-C have been shown to be associated with
insulin resistance. The fact that these metabolic abnormal-
ities cluster in many individuals gave rise to the term
“metabolic syndrome” (MS). Reaven was the first to refer
to this accumulation of above mentioned dyslipidemia and
high blood pressure as MS X [9]. It took many years to
develop the definition of MS; the latest MS “harmonizing
definition” is based on the presence of 3 or more of the five
risk factors (Table 1). At present, MS is seen as a pro-
atherosclerotic, pro-inflammatory and pro-coagulative sta-
tus with a high risk for the premature development of
atherosclerosis, CVD and T2DM [10]. All the established
risk factors developing against the background of insulin
resistance worsen with age and unhealthy lifestyle.
Subjects with MS and/or impaired glucose homeostasis
are at an increased risk for premature atherosclerosis and,
conversely, patients with established CVD are at high risk
for metabolic disorders associated with insulin resistance
[11]. The cardiovascular risk profile for CVD coincides
with the risk profile for T2DM which is why the terms
cardio-metabolic risk profile and cardio-metabolic risk
seem to be more appropriate and logical.
Policy and strategies in cardiovascular disease
prevention and assessment of individual cardiovascular
risk in primary prevention
Three strategies for the prevention of CVD are distin-
guished: population and high risk strategies in primary and
secondary prevention among patients with manifest CVD.
The population strategy is critical to reducing the overall
incidence of CVD since it is designed to reduce risk factors
at the population level. This population approach of
recommendation and implementation of a healthy lifestyle,
i.e., avoidance of tobacco smoking, healthy food choices,
adequate physical activity and avoiding overweight and
obesity, is not possible to achieve without national, and
especially international community organizations and polit-
ical institutions, e.g., national government, European Union
(EU), WHO, etc. A new initiative, the European Heart
Health Charter, was launched by the European Society of
Cardiology, EU, and the European Heart Network in
partnership with WHO (www.heartcharter.eu). The Europe-
an Heart Health Charter advocates the development and
implementation of comprehensive health strategies, meas-
ures and policies at European, national, regional and local
levels that promote cardiovascular health and prevent CVD.
The European Guidelines on cardiovascular disease pre-
vention in clinical practice (the Fourth Task Force of the
European Society of Cardiology and Other Societies on
CVD Prevention in Clinical Practice) are intended to assist
physicians and other health professionals to be successful in
this endeavor, particularly in terms of employing effective
preventive measures in day-to-day clinical practice [3].
The high risk strategy approach represents the physi-
cian’s model in the primary prevention of CVD. In
relatively healthy subjects without any manifest CVD, the
risk chart should be used to estimate the global cardiovas-
cular risk. The first risk chart,“the Framingham risk score”,
available since 1967 includes the following major (stan-
dard) risk factors: gender, age, tobacco smoking, systolic
blood pressure and total C level. The absolute risk, i.e., the
probability (%) of non-fatal or fatal coronary events for the
next 10 years, was estimated in each person in the primary
prevention of CVD according to the above risk factors.
There were several problems with this chart; because the
data were derived from the American population, and
obtained from the not very large Framingham study, only
coronary events could be assessed. In 2003, a new risk
chart was introduced in the European Guidelines on CVD
Prevention:“SCORE—European High (Low) Risk Chart”
based on the data from 12 European CVD mortality
Table 1 Definition of metabolic syndrome [10]
Waist circumference > 88 cm in women
> 102 cm in men
Blood pressure* ≥ 130/85 mmHg
Fasting triglycerides level* ≥ 1.7 mmol/L
HDL (high-density lipoprotein)
– cholesterol* < 1.3 mmol/L in women
< 1.0 mmol/L in men
Fasting glucose level* ≥ 5.6 mmol/L
* or specific drug treatment
18 EPMA Journal (2011) 2:15–26
population studies including more than 200,000 men and
women [12]; regrettably, non-fatal events were not evalu-
ated in these studies. Two types of Score risk charts are
currently available, one estimating cardiovascular risk
based on standard risk factors, i.e., gender, age, smoking,
systolic blood pressure and plasma total C level, and the other
for subjects with low HDL-C levels (below 1.3 mmol/L in
women and below 1.0 mmol/L in men) on the basis of the
above standard risk factors, with the only difference being that
total C level is replaced by total C/HDL-C levels. More
recently, some European countries including the Czech
Republic, developed their own Score risk charts based on
the fatal events reported from their own population studies
[13]. An example of the SCORE Risk Chart for the high risk
European countries is shown in Fig. 3.
Assessment of the absolute global risk for CVD in
asymptomatic persons reflects the personalized approach of
the prediction and prevention of CVD, with healthcare
differentiated according to the actual individualized risk
score. The absolute risk may be higher than indicated in the
chart; e.g., in sedentary or obese subjects, especially those
with abdominal obesity, those with a strong family history
of premature CVD, the socially deprived, those with low
HDL-C or high TG, and in asymptomatic subjects with
evidence of pre-clinical atherosclerosis, e.g., a reduced
ankle-brachial index, or documented by imaging techniques
such as carotid ultrasound or computed tomography, etc. A
very intensive healthcare concerning lifestyle improvement
and pharmacological treatment of risk factors is necessary
in high risk subjects with a 5% or higher probability of any
fatal CVD over the next 10 years. Subjects with a low
global CV risk have to pursue a healthy lifestyle to maintain
a low CV risk. It is necessary to look for other metabolic
risk factors, especially those not included in the Risk Score
tables yet. Subjects with intermediate CV risk (3–5%) make
up the majority of the general population; however, while
having average risk factors levels, they develop a high
number of CV events.
There is evidence to suggest that the current risk
assessment algorithm using traditional risk factors may not
estimate the global CV risk accurately, especially in patients
with insulin resistance and accompanying risk factors such as
abdominal obesity, atherogenic dyslipidemia (high TG and
reduced HDL-C levels), impaired glucose homeostasis, etc.
Many studies have compared the performance of the classical
tools of CV risk evaluation (Framingham risk score, SCORE
Risk Chart) and MS in CVD prediction. The presence of MS
usually does not impact the risk in subjects at high risk,
whereas the presence of MS in subjects at low or intermediate
risk significantly increases the probability of developing
CVD, making it imperative to improve their global cardio-
metabolic risk assessment.
Fig. 3 SCORE - European Low
Risk Chart [3]
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Risk factors associated with insulin resistance,
biomarkers and imaging procedures could improve
cardio-metabolic risk assessment
Metabolic syndrome and type 2 diabetes mellitus
It should be noted that the five risk factors of MS
summarized in Table 1 were proposed by expert consensus
while not tested for their ability to allow for the
identification of individuals both with MS and the related
increase in CVD risk [14]. Clinicians have often been
confused by the conceptual definition of MS with the
proposed criteria. The risk factors of MS are surrogate
variables simply reached in clinical practice to identify high
risk subjects. The dichotomously divided five risk factors
should help clinicians unable to measure insulin resistance
using very difficult and time consuming methods such as
the euglycemic hyperinsulinemic clamp or the insulin
suppression test, accurately measure visceral adiposity by
expensive computed tomography or magnetic resonance
imaging, etc.
The concept of MS, a syndrome of abnormalities linked
to insulin resistance, was introduced by Reaven in
California in 1988 [9]. He proposed that impaired insulin
action and compensatory hyperinsulinemia were both part
of the MS cluster, together with elevated blood pressure,
hypertriglyceridemia and low HDL-C. As Reaven and his
colleague found insulin resistance, as assessed by the
insulin suppression test, also in lean subjects, their
definition of MS did not include obesity. Much earlier,
Vague drew attention to the importance of abdominal
adiposity (upper body adiposity, android or male type
obesity are synonymous) as a risk factor for CVD and
T2DM [15]. The use of very sophisticated imaging
techniques, e.g., computed tomography or magnetic reso-
nance imaging, to measure abdominal fat accumulation, has
shown that independently of the presence or absence of
clinical obesity defined as BMI≥30 kg/m2, an increase of
intraabdominal or visceral adipose tissue correlates signif-
icantly with the occurrence of MS and other known CV risk
factors.
Waist circumference
Waist circumference reflects abdominal distribution of
adipose tissue and is a most simple non-time consuming
method for everyday practice. It is recommended to
measure waist circumference in the upright position, at
mid-distance between the chest and the spina illiaca anterior
superior, when the subject has exhaled. Waist circumfer-
ence values >94 (or >102) cm in males and >80 (or >88)
cm in females are significantly associated with overweight
(or abdominal obesity) and high CV and metabolic risk.
However, the above values are not enough for the clinical
identification of high risk subjects for CVD and T2DM.
Several groups have reported that an increase in waist
circumference and fasting TG levels (described as the
hypertriglyceridemic waist) may be relevant and readily
screened measures to identify subjects at high risk of MS
[16]. Reduction of waist circumference by diet or pharma-
cological treatment in obese subjects leads to a reduction of
intra-abdominal fat while improving insulin resistance and
reducing the CVD and metabolic risk as shown by the
Quebec Cardiovascular Study [17].
Blood pressure
Casual blood pressure (BP) is one of the traditional
cardiovascular risk factors, a BP≥130/80 mmHg, including
high normal BP=130–139/80–89 mmHg, is associated with
a higher CV and metabolic risk than a BP<130/80 mmHg
[18]. This association is known in primary preventive
studies of CVD only. In secondary CVD prevention, and
especially in patients with heart failure, a BP below 130/80
is consistent with a worse prognosis compared with
subjects treated to achieve have BP below 140/90 but not
less than 130/80 mmHg [19]. It is very well known from
interventional studies that a healthy lifestyle, characterized
especially by a rational diet with reduced salt intake, regular
physical activity and non-smoking, is advisable in subjects
with high normal BP. Antihypertensive drugs are indicated
in subjects with repeatedly high BP≥140/90 mmHg and
high global CVD risk. Numerous pharmacological trials
have clearly demonstrated that personalized treatment of
hypertension is needed. In hypertensive patients with
metabolic disorders such as MS or T2DM, inhibitors of
the renin-angiotensin system (RAS) are the first choice
drugs (ACE inhibitors or angiotensin II receptors blockers).
These drugs do not only reduce BP but also improve insulin
resistance while not worsening lipid metabolism. Antihy-
pertensive treatment by RAS inhibitors reduces CV risk
and, also, the risk for development of T2DM, which is the
most important effect in subjects with MS. Combination
therapy is very often needed to achieve a BP <140/
90 mmHg [3]. Calcium channel blockers, metabolically
neutral indapamid/metapamid or centrally acting antihyper-
tensives stimulating imidazoline receptors in the central
nervous system are suitable for combination with RAS
inhibitors in patients with MS or T2DM.
Dyslipidemia
Low density lipoprotein cholesterol (LDL-C) is considered
the main risk factor for atherosclerosis and CVD; LDL
particles are involved in the atherosclerotic process, and the
higher LDL-C, the higher CV risk. Recommended levels of
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total and LDL-C are below 5 mmol/L and below 3 mmol/L,
respectively in subjects in primary CVD prevention. On
the other hand, more reduced levels of total and LDL-C
(the higher the CVD risk, the lower LDL-C) are
recommended in patients with manifest CVD or with
T2DM. Reducing LDL-C levels by statin therapy will
lower the incidence of CVD by up to one third. Although
impressive, these results also raise the question of how to
decrease the residual relative 70% risk of CVD events
that still occur? Atherogenic dyslipidemia is one of the targets
of current research, with the Residual Risk Reduction
Initiative (R3i), a non-profit organization, established to
address this important issue [20].
Some clinical and epidemiological studies showed
recently that high TG levels are also associated with higher
CV risk than TG levels below 1.7 mmol/L. Triglyceride
levels are determined as part of standard biochemical
venous blood sample screening. In fact, TGs are the most
problematic particles in terms of CV risk prediction and
prevention of atherosclerosis. Triglyceride-rich particles are
most heterogeneous; they are known to be present in
chylomicrons,VLDL, IDL and, in smaller amounts in LDL,
which is why TG levels in multifactorial studies were not
always assessed as an independent CVD risk factor. This
explains why apolipoproteins B (part of atherogenic lipid
particles LDL, VLDL, IDL) and apolipoproteins A (part of
the anti-atherogenic particles HDL), and their ratio predict
CVD risk more precisely as showed in, e.g., the Interheart
study [5]. Triglyceride levels above 1.7 mmol/L are known
to be associated with the presence of small dense LDL
particles which are very atherogenic, susceptible to oxida-
tion and glycation, and resistant to the LDL receptors. All
these features explain their high atherogenic activity.
Elevated TG levels, small dense LDL particles and low
HDL-C are called the lipid triad characterized by athero-
genic dyslipidemia that often occurs in subjects with MS or
T2DM [21].
Plasma HDL-C is considered a cardioprotective lipid
particle independent of other major CV risk factors. It has
been long known (since the 1950s) that the lower the HDL-
C levels, the higher the CV risk in both genders [22]. The
outcomes of clinical trials evaluating HDL-C-raising
therapies lack the strength and consistency of the statin
trials data. Torcetrapib therapy in subjects with reduced
HDL-C levels was stopped and the drug was withdrawn
from the market because of a significant increase in CVD
mortality in addition to a significant rise in HDL-C.
Extensive evidence shows that elevated TG and low
HDL-C are both predictors for CVD independent of LDL-
C. Non-fasting TG levels, measured 2–4 h postprandially,
may be of even greater relevance to CVD risk since
atherogenic lipoprotein remnants secreted by the liver and
intestine postprandially circulate at higher concentrations
than in the fasting state, as supported by evidence from
clinical studies [23].
Furthermore, the total C/HDL-C ratio also needs to be
taken into account, as shown by the Prospective Cardio-
vascular Münster (PROCAM) study. In this study, one in
seven subjects with a combination of a high total C/HDL-C
ratio (>5.0), low HDL-C (<0.90 mmol/L) and elevated TG
(>2.26 mmol/L) experienced myocardial infarction [24].
Many other atherogenic indexes are used for atherosclerosis
prediction, e.g., the ratio of fasting TG to HDL-C has been
shown to be a good marker of insulin resistance [25].
Some years ago, Dobiasova and Frohlich proposed an
atherogenic index of plasma levels of TG and HDL-C:
AIP = log [TG/HDL-C] [26]. Logarithmic transformation of
the molar concentrations of TG and HDL-C is closely
related to the sizes of HDL-C, LDL-C and VLDL-C
particles, which are now considered to be new-generation
indicators of CV risk and define the atherogenic genotype
of plasma more precisely than classical biochemical
markers such as LDL-C, HDL-C, total-C, apolipoprotein
B or A, etc. The authors have improved that AIP can be
used for monitoring the actual lipoprotein profile and
predicting CV risk. Increased TG levels are associated with
increased levels of atherogenic lipid particles (in particular
LDL and VLDL) and increased rates of transport of
cholesterol esters from HDL particles to lipoprotein-
containing Apo-B. While the levels of TG alone are not
an independent risk marker, they do serve as a regulator of
lipoprotein interactions. Some studies have shown that AIP
may be an important tool for analyzing the results of
clinical trials [27].
Regarding T2DM patients, only data from the ACCORD
trial are available; only in those diabetic patients with
atherogenic dyslipidemia defined as TG≥2.3 mmol/L with
HDL-C<0.9 mmol/L did combination hypolipidemic ther-
apy with simvastatin plus fenofibrate reduce CVD risk as
compared with T2DM patients without this atherogenic
dyslipidemia [28]. No data are available on the treatment of
atherogenic dyslipidemia in subjects without T2DM, e.g.,
in subjects with MS. Preventive cardiologists suggest that
more studies and more pharmacological trials for athero-
genic dyslipidemia treatment are warranted to obtain a
larger body of evidence.
Glucose
Elevated fasting plasma glucose level is also considered an
independent risk factor for CVD; it is especially the
postprandial glucose level that is better predictive for CV
risk and risk for T2DM.
A fasting glucose level of more than 5.6 and less than
7.0 mmol/L is considered impaired fasting glucose and only
a proportion of these subjects also have impaired glucose
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tolerance as assessed by oral glucose tolerance test (oGTT).
If the glucose level at 2 h after oral 75 g poor glucose intake
is found to be between 7.8 and 11 mmol/L; impaired
fasting glucose and impaired glucose tolerance are often
called “prediabetes”. Levels of 11 mmol/L and higher at
2 h of oGTT are considered T2DM. Pharmacological
reduction of hyperglycemia is recommended in diabetic
patients (repeatedly increased fasting plasma glucose of
7 mmol/L or oGTT, see above) only and metformin is
drug of the first choice. A reduction of CVD morbidity
and mortality was documented in the UKPDS study
(United Kingdom Prospective Diabetes Study) in obese
patients with newly diagnosed T2DM. Other studies have
found many discrepancies in terms of antidiabetic
pharmacological treatment and CVD risk. Whilst some
old oral antidiabetic drugs increased CVD risk, the new
ones are more efficient not only for hyperglycemia but,
also, in the prevention of CVD. As shown in the most
recent pharmacological trials, glucose control in patients
with diabetes has to be individualized. Intensive anti-
diabetic therapy is recommended in newly diagnosed
T2DM as against T2DM of long duration. Intensive
therapy with glucose-lowering drugs produces a number
of hypoglycemic events and increases the CV risk in
patients with long duration of T2DM [29]. All glucose
disorders described above including T2DM may be
present in subjects with MS.
Should fasting or postprandial glucose levels or glyco-
sylated hemoglobin (HbA1C) levels be included into the
CVD risk assessment to improve the accuracy of cardio-
metabolic risk assessment? The only CVD risk score,
which is the only one of its kind including impaired fasting
glucose and impaired glucose tolerance in the risk function
determination was developed by the DECODE group
(Diabetes Epidemiology: Collaborative analysis Of Diag-
nostic criteria in Europe) [30]. The Finnish Diabetes Risk
Score (FINDRISC) predicts the 10-year risk for developing
T2DM with an 85% accuracy. It is based on a questionnaire
suitable for the general population to identify subjects at
high risk for T2DM. Its items include age, BMI, waist
circumference, physical activity, diet, information about
hypertension, glucose level from the past and family history
of diabetes; sum of the points related to the specific answer
shows the total score of risk for developing T2DM within
10 years. In addition, FINDRISC predicts the incidence of
myocardial infarction and stroke [31].
High-sensitivity C-reactive protein, albuminuria, and brain
natriuretic peptide as biomarkers
Various biomarkers have been investigated to improve the
prediction of individual cardio-metabolic risk in subjects
from the general population over the last two decades.
Many of these markers associate with inflammation which
plays an important role in all stages of the atherosclerotic
process.
C-reactive protein evaluated by the high sensitivity method
(hs-CRP)
High sensitivity CRP is an acute phase protein belonging to
the family of proteins known as pentraxins; it is synthesized
primarily by hepatocytes but, also, by macrophages and
smooth muscle cells. It is a marker of systemic inflamma-
tion. Recently, our research group found in patients with
T2DM that hs-CRP≥3 mg/L is a common feature,
particularly in diabetics with abdominal obesity who meet
the criteria of MS. Waist circumference (but not body mass
index) appeared to be a major variable associated with
increased hs-CRP independent of age and sex in our study
[32]. High sensitivity CRP has been shown to be an
independent predictive factor for CVD and, also, for MS
[33]. The largest meta-analysis to date has included
individual records of 160,309 people without a history of
vascular disease from 54 long-term prospective studies;
CRP levels were linearly associated with several conven-
tional risk factors and inflammatory markers, and nearly
linearly with the risk of ischemic vascular disease and non-
vascular mortality. Risk ratios (RRs) for coronary heart
disease per 1-SD higher log CRP levels (three times higher)
were 1.63 (95% CI 1.51–1.76) when initially adjusted for
age and sex only, and 1.37 (1.27–1.48) when further
adjusted for conventional risk factors; 1.44 (1.32–1.57),
and 1.27 (1.15–1.40) for ischemic stroke; 1.71 (1.53–1.91),
and 1.55 (1.37–1.76) for vascular mortality. The authors
summarized in the meta-analysis that hs-CRP levels
showed continuous associations with the risk of coronary
heart disease, ischemic stroke, and vascular mortality [34].
C-reactive protein, as assessed by the high sensitivity
method, seems to be actually independent and may be a
causal risk factor for CVD and T2DM in the near future. Its
levels are affected by genetic polymorphisms and environ-
mental factors (especially by dietary components). It is
known from many pharmacological studies that statins or
fibrates can reduce hs-CRP levels in some patients. Future
studies focusing on the effects and interactions of genetic
variation on the hs-CRP response to dietary and other
behavior modifications as well as drug treatment could
have important implications for the development of more
personalized preventive and therapeutic approaches to
reduce cardio-metabolic risk.
Albuminuria (AU)
Albuminuria is defined as excretion of albumin in the urine;
microalbuminuria 30–300 mg/24 h, macroalbuminuria>
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300 mg/24 h, and/or reduced glomerular filtration rate
(GFR)<60 mL/min were both recognized as significant risk
factors for CVD and glucose metabolism disorders such as
T2DM [3]. Albuminuria reflects injury to the endothelium,
not only in glomerular endothelium but, also, the endothe-
lium of other arteries of the body. Albuminuria was
associated not only with impaired renal function but, also,
with CV risk, metabolic risk, and total mortality [35]. A
more precious method is the expression of AU as the
creatine/albumin ratio (UACR, in mg/mmol). A simple
semiquantitative method using the dipstick test is recom-
mended in all patients with arterial hypertension and/or
diabetes. Albuminuria is reduced by a healthy lifestyle,
especially after giving up smoking or after treatment of
hypertension (RAS inhibitors are very effective in reducing
AU independently of systematic blood pressure reduction)
or hyperglycemia [36, 37].
Given the increasing prevalence of T2DM and renal
diseases, widespread use of the dipstick test in the general
population is still under debate. However, the AU dipstick
test is an easy and inexpensive test for the identification of
subjects with cardio-metabolic and renal risk; a positive
finding of AU has to be related to other specific risk factors
for the above diseases.
N-terminal pro-brain natriuretic peptide (Nt-proBNP)
Brain natriuretic peptide is considered a very useful clinical
marker and predictor for diagnosis and prognosis, respec-
tively, in patients with heart failure in clinical practice [38].
Our research group has shown recently that the elevation of
Nt-proBNP increased more than three times the RR for total
mortality in asymptomatic patients with stable coronary
heart disease [39].
There are less data concerning Nt-proBNP in the
prediction of CV and metabolic risk in primary prevention.
Our colleagues from the Research Center for Prevention
and Health from Glostrup University Hospital in Denmark
showed, in a general population sample, that hs-CRP was
primarily related to metabolic CV risk factors whereas Nt
pro-BNP was primarily related to hemodynamic risk
factors and urinary albumin/creatinine ratio (UACR)
related to both hemodynamic CV risk and metabolic risk
factors [40].
Only a small number of biomarkers was analyzed
comprehensively with traditional CV risk factors and/or
known markers of vascular damage. Many of these
biomarkers were significantly associated with cardio-
metabolic risk in bifactorial analysis, many of them lost
their significance in multifactorial analysis, i.e., after
adjustment for the standard risk factors having a stronger
statistical power than the emerging risk factors. These
results from large prospective randomized epidemiological
studies using standard sophisticated statistical methods are
considered to be the most relevant for clinical practice,
so-called evidence-based medicine data. It is the epidemio-
logical approach, used also in interventional studies, which is
the most important for the evaluation of risk factor causality.
On the other hand, there are many individual combinations
of known risk factors, emerging risk factors, etc., and our
ultimate goal is to identify some markers or group of markers
to more precisely determining absolute personalized risk for
atherosclerosis and/or metabolic disorders and then institute
personalized preventive measures early enough to stop the
development of the disease.
Imaging techniques
A host of new imaging techniques have come into use over
the last 10 years; these include computed tomography (CT)
angiography, calcium score assessment by CT, magnetic
resonance imaging, etc. Most of them are not suitable for
primary preventive screening in the general population.
Carotid intima-media thickness
Ultrasound carotid intima-media thickness (CIMT) mea-
surement is a non-invasive, reproducible, inexpensive, and
radiation-free screening test. Recent data have improved
our understanding of the application of CIMT as a
screening tool for CVD. Carotid intima-media thickness
measurement may move an individual into a higher- or
lower-risk category, allowing for appropriate institution of
preventive strategies. The predictive value is better for
stroke than for cardiac events. Nevertheless, coronary heart
disease prediction by CIMT is inferior to that by ultrasound
carotid plaque assessment as the plaque may be more
representative of atherosclerosis than CIMT. In the Finnish
population-based Health 2000 Survey, CIMT was used as a
marker of subclinical atherosclerosis. In multivariate mod-
els, MS was an independent determinant of CIMT in both
sexes (p≤0.001 for both). When MS was included into the
regression models along with its components, it was an
independent determinant of CIMT in women but not in
men. After dividing the population into risk categories
according to the Framingham risk score and the presence of
MS, the Framingham risk score predominantly determined
CIMT regardless of the presence of MS in men. However,
in women, CIMT was significantly higher in subjects with
MS than in those without it, independently of the Framing-
ham risk score. In conclusion, MS is an independent
determinant of CIMT in both sexes. In women, but not in
men, MS is associated with CIMT independently of its
components and provides additional information on a
person’s risk for early atherosclerosis beyond the Framing-
ham risk score in women, but not in men [41].
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Coronary calcium
Coronary calcium in the coronary arteries wall is a
marker of the presence of atherosclerosis. The assessment
is most often performed using multislice computed
tomography, with the calcifications quantified by the
Agatston score (CAC). CAC can not be interpreted
mechanically; it has the strongest association with age
and male gender [42]. Subjects with MS and T2DM have
been shown to have more likely higher CAC than the
general population [43, 44]. The prognostic value of CAC
is shown in the Table 2. The predictive CAC value was
shown, e.g., in a follow-up of 11, 000 patients undergoing
a screening medical examination including the CAC score
in 1995–2000. During a mean follow-up period of
3.5 years in asymptomatic men and women, CVD events
(non-fatal myocardial infarction and CVD-related deaths)
were higher with a CAC score >400 [45]. A negative
CAC shows a strong negative predictive value for future
CVD events and the presence of plaques is uncommon in
these subjects [46]. In contrast to hs-CRP or CIMT, there
is actually no possibility to significantly modulate CAC by
treatment of standard risk factors, e.g., by the statin
therapy of hyperlipidemia [47].
At present, routine quantification of CAC progression
cannot be recommended in clinical practice because of the
lack of clinical data and protocols [48]. There is no
significant correlation between CAC and myocardial stress
testing [49], and stress testing or coronary angiography in
asymptomatic subjects with high CAC is not recommen-
ded. In conclusion, CAC is considered a marker of stable
atherosclerotic disease with an important predictive value
for CVD. The major limitations of CAC are its cost and
radiation.
A very interesting question remains to be answered.
What is the background of the association between MS,
CIMT, and CAC? The Atherosclerosis Risk in Communi-
ties (ARIC) study could explain a part of the above
question. A sample of 7260 non-diabetic Caucasian
individuals with IMT measurement and relevant genotyping
was formed and a fasting glucose genetic risk score
developed according to the strength of genes influencing
the fasting glucose. This genetic score was significantly
associated (p=0.009) with mean CIMT. The significant
association of the fasting glucose genetic risk score with
IMT suggests a possible a causal association of elevated
fasting glucose with atherosclerosis (although it may be that
these loci affect IMT through non-glucose pathways) [50].
Another genetic survey explored a genetic variant of
T2DM strongly associated with CAC. In contrast, variants
near insulin-like growth factor-binding protein, transcrip-
tion factors, several transporters were clearly associated
with diabetes; no evidence for an association with CAC
was observable. This differential association pattern under-
lines the potential of endophenotypes such as CAC, to
extend the scope of disease outcome [51]. In conclusion, it
is clear that the relationships between the findings of
imaging and laboratory methods are based on a strong
genetic background.
Both non-invasive imaging methods, CAC and CIMT,
are significant predictors of CVD and are significantly
associated with MS. Although CIMT is less expensive with
no radiation, CAC shows a better prognostic value.
Conclusion and main messages
Recent clinical studies have shown that the traditional CV
risk prediction score system needs further improvement,
because the majority of CV events occurs in intermediate-
or partly in low-risk groups of the population. Many
metabolic risk factors, markers or predictors have been
identified during the last two decades. It is especially
because of the risk factor clustering that MS needs to be
focused on in personalized prediction and early prevention
of premature atherosclerosis. The increasing prevalence of
T2DM is a consequence of an unhealthy lifestyle, partic-
ularly sedentary habits and high energy food intake on one
hand, and late identification and start of treatment of cardio-
metabolic risk factors on the other.
New biomarkers, hs-CRP, abuminuria and Nt-proBNP
are associated with the standard CV risk factors (age, sex,
tobacco smoking, high blood pressure and high plasma
cholesterol), and seem to be useful predictors in cardio-
metabolic risk assessment. However, sophisticated imaging
techniques such as carotid intima-media thickness, presence
of atherosclerotic plaques or high coronary artery CAC,
could improve cardio-metabolic risk prediction; their use in
primary prevention is limited, because some of them are too
expensive, time-consuming, and invasive in radiation.
The efficacy of preventive tools, especially of CVD and
T2DM primary prevention, depends on the personalized
approach to subjects at high cardio-metabolic risk in the
general population. It is particularly general practitioners
who are responsible for preventive screening and identifi-
cation of subjects at high cardio-metabolic risk. Well-
Table 2 Agatston score and cardiovascular risk [48]
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educated general practitioners, with the help of all other
specialists, have to implement preventive measures and
start interventions early and rationally according to latest
concepts in evidence-based medicine.
The many barriers to better CVD and T2DM prevention
are still evident. In fact, they reflect the difficulty in making
accurate CVD risk estimation in the clinical setting,
particularly in the intermediate-risk subjects. The limita-
tions of CVD risk prediction tools such as underutilization
of the current CVD risk calculators, especially in primary
care, are obvious. An additional barrier is the failure to
effectively implement guideline recommendations on risk
factors management and CVD prevention.
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